<DOC>
	<DOC>NCT01025206</DOC>
	<brief_summary>This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.</brief_summary>
	<brief_title>A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Advanced Myeloma with measurable disease after at least 2 previous regimens. Life expectancy &gt; 3 months. Performance status ECOG &lt; 2. Prior antineoplastic therapy within 4 weeks prior to inclusion. No high dose steroids within 7 days prior to screening. Severe other conditions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>